Stay updated on Pembrolizumab for Refractory Esophageal Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating an update in the study completion date for the Phase II clinical trial evaluating Pembrolizumab in refractory advanced esophageal cancer, with the primary completion date now set at 2019-07-23.
    Difference
    0.1%
    Check dated 2024-06-06T14:48:43.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for participation in the study.
    Difference
    56%
    Check dated 2024-05-22T21:36:12.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:36:02.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Refractory Esophageal Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Refractory Esophageal Cancer Clinical Trial page.